Search research articles
Contact Us
Filters
Showing results (161-170 of 174) with videos related to
Page
of 18
Sort By:
Clinical Genitourinary Cancer
|
May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
European Urology
|
December 3, 2014
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)
Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Scientific Reports
|
July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Laura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
The Lancet. Oncology
|
January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais, et al.
Journal of Cellular Physiology
|
December 12, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience
Laura Pizzuti, Antonio Giordano, Andrea Michelotti, et al.
Journal of Cellular Physiology
|
January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
Eriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Frontiers in Oncology
|
June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational study
Francesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
Page
of 18
Search research articles
Search
Showing results (161-170 of 174) with videos related to
Sort By:
Page
of 18
Clinical Genitourinary Cancer
|
May 14, 2018
Safety and Efficacy of Cabozantinib in Metastatic Renal-Cell Carcinoma: Real-World Data From an Italian Managed Access Program
Giuseppe Procopio, Michele Prisciandaro, Roberto Iacovelli, et al.
European Urology
|
December 3, 2014
Clinical Outcomes of Castration-resistant Prostate Cancer Treatments Administered as Third or Fourth Line Following Failure of Docetaxel and Other Second-line Treatment: Results of an Italian Multicentre Study
Orazio Caffo, Ugo De Giorgi, Lucia Fratino, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
March 31, 2021
Impact of Baseline and On-Treatment Glycemia on Everolimus-Exemestane Efficacy in Patients with Hormone Receptor-Positive Advanced Breast Cancer (EVERMET)
Claudio Vernieri, Federico Nichetti, Luca Lalli, et al.
Journal of Experimental & Clinical Cancer Research : CR
|
December 11, 2020
Loss of HER2 and decreased T-DM1 efficacy in HER2 positive advanced breast cancer treated with dual HER2 blockade: the SePHER Study
Giulia Bon, Laura Pizzuti, Valentina Laquintana, et al.
Scientific Reports
|
July 3, 2021
The prognostic relevance of HER2-positivity gain in metastatic breast cancer in the ChangeHER trial
Laura Pizzuti, Maddalena Barba, Marco Mazzotta, et al.
The Lancet. Oncology
|
January 31, 2012
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell, Enric Carcereny, Radj Gervais, et al.
Journal of Cellular Physiology
|
December 12, 2018
Palbociclib plus endocrine therapy in HER2 negative, hormonal receptor-positive, advanced breast cancer: A real-world experience
Laura Pizzuti, Antonio Giordano, Andrea Michelotti, et al.
Journal of Cellular Physiology
|
January 17, 2020
Impact of BMI on HER2+ metastatic breast cancer patients treated with pertuzumab and/or trastuzumab emtansine. Real-world evidence
Eriseld Krasniqi, Laura Pizzuti, Giacomo Barchiesi, et al.
Therapeutic Advances in Medical Oncology
|
February 17, 2022
PANHER study: a 20-year treatment outcome analysis from a multicentre observational study of HER2-positive advanced breast cancer patients from the real-world setting
Laura Pizzuti, Eriseld Krasniqi, Isabella Sperduti, et al.
Frontiers in Oncology
|
June 1, 2023
Adjuvant capecitabine in triple negative breast cancer patients with residual disease after neoadjuvant treatment: real-world evidence from <i>CaRe</i>, a multicentric, observational study
Francesca Sofia Di Lisa, Eriseld Krasniqi, Laura Pizzuti, et al.
Page
of 18